YiChang HEC ChangJiang Pharmaceutical Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Juncai Jiang
Chief executive officer
CN¥3.3m
Total compensation
| CEO salary percentage | 14.61% |
| CEO tenure | 10yrs |
| CEO ownership | 0.008% |
| Management average tenure | 7.8yrs |
| Board average tenure | 7.8yrs |
Recent management updates
Recent updates
YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) 26% Jump Shows Its Popularity With Investors
May 12
YiChang HEC ChangJiang Pharmaceutical's (HKG:1558) Conservative Accounting Might Explain Soft Earnings
May 05Earnings Working Against YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Share Price
Jan 24YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Strong Profits May Be Masking Some Underlying Issues
Oct 07Should You Be Adding YiChang HEC ChangJiang Pharmaceutical (HKG:1558) To Your Watchlist Today?
Sep 19YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Popularity With Investors Under Threat As Stock Sinks 26%
May 29Do YiChang HEC ChangJiang Pharmaceutical's (HKG:1558) Earnings Warrant Your Attention?
Apr 23YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) P/S Is Still On The Mark Following 33% Share Price Bounce
Mar 01Investors Appear Satisfied With YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Prospects As Shares Rocket 33%
Mar 01YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Business Is Trailing The Industry But Its Shares Aren't
Jan 03YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Could Easily Take On More Debt
Sep 25Does YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Have A Healthy Balance Sheet?
Nov 25Is YiChang HEC ChangJiang Pharmaceutical (HKG:1558) A Risky Investment?
Mar 23Does This Valuation Of YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (HKG:1558) Imply Investors Are Overpaying?
Oct 29Here's Why YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Has A Meaningful Debt Burden
Apr 13YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (HKG:1558) Analysts Just Cut Their EPS Forecasts Substantially
Mar 23YiChang HEC ChangJiang Pharmaceutical's(HKG:1558) Share Price Is Down 55% Over The Past Three Years.
Mar 13YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Is Growing Earnings But Are They A Good Guide?
Feb 20
Do Institutions Own YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (HKG:1558) Shares?
Feb 02YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Dec 26Key Things To Watch Out For If You Are After YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) 5.1% Dividend
Dec 13What Type Of Returns Would YiChang HEC ChangJiang Pharmaceutical's(HKG:1558) Shareholders Have Earned If They Purchased Their SharesYear Ago?
Nov 30CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2024 | CN¥3m | CN¥487k | CN¥483m |
| Sep 30 2024 | n/a | n/a | CN¥1b |
| Jun 30 2024 | n/a | n/a | CN¥2b |
| Mar 31 2024 | n/a | n/a | CN¥2b |
| Dec 31 2023 | CN¥3m | CN¥482k | CN¥2b |
| Sep 30 2023 | n/a | n/a | CN¥2b |
| Jun 30 2023 | n/a | n/a | CN¥1b |
| Mar 31 2023 | n/a | n/a | CN¥608m |
| Dec 31 2022 | CN¥1m | CN¥600k | CN¥77m |
| Sep 30 2022 | n/a | n/a | -CN¥18m |
| Jun 30 2022 | n/a | n/a | -CN¥113m |
| Mar 31 2022 | n/a | n/a | -CN¥351m |
| Dec 31 2021 | CN¥1m | CN¥490k | -CN¥588m |
| Sep 30 2021 | n/a | n/a | -CN¥436m |
| Jun 30 2021 | n/a | n/a | -CN¥285m |
| Mar 31 2021 | n/a | n/a | CN¥277m |
| Dec 31 2020 | CN¥756k | CN¥229k | CN¥839m |
| Sep 30 2020 | n/a | n/a | CN¥1b |
| Jun 30 2020 | n/a | n/a | CN¥2b |
| Mar 31 2020 | n/a | n/a | CN¥2b |
| Dec 31 2019 | CN¥393k | CN¥222k | CN¥2b |
| Sep 30 2019 | n/a | n/a | CN¥2b |
| Jun 30 2019 | n/a | n/a | CN¥1b |
| Mar 31 2019 | n/a | n/a | CN¥1b |
| Dec 31 2018 | CN¥365k | CN¥209k | CN¥943m |
Compensation vs Market: Juncai's total compensation ($USD462.80K) is about average for companies of similar size in the Hong Kong market ($USD501.92K).
Compensation vs Earnings: Juncai's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
CEO
Juncai Jiang (42 yo)
10yrs
Tenure
CN¥3,334,000
Compensation
Mr. Juncai Jiang has been General Manager and Executive Director of YiChang HEC ChangJiang Pharmaceutical Co., Ltd. since joining in May 2015. Mr. Jiang served as Deputy Head of the traditional Chinese med...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Executive Director | 10yrs | CN¥3.33m | 0.0076% HK$ 873.6k | |
| CFO & Head of Finance Department | 6.3yrs | CN¥683.21k | no data | |
| Deputy GM & Executive Director | 10yrs | CN¥3.07m | 0.0076% HK$ 879.4k | |
| Deputy GM & Executive Director | 10yrs | CN¥1.82m | 0.0076% HK$ 873.6k | |
| Executive Director | 1.7yrs | CN¥1.86m | no data | |
| Joint Company Secretary | 6.6yrs | CN¥370.31k | no data | |
| Head of the Sales Department | 11yrs | CN¥645.00k | no data | |
| Chief of Quality Division & Employee Representative Supervisor | 7.8yrs | no data | 0.0036% HK$ 419.0k | |
| Joint Company Secretary | 3.3yrs | no data | no data |
7.8yrs
Average Tenure
43yo
Average Age
Experienced Management: 1558's management team is seasoned and experienced (7.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Executive Director | 10yrs | CN¥3.33m | 0.0076% HK$ 873.6k | |
| Deputy GM & Executive Director | 19.3yrs | CN¥3.07m | 0.0076% HK$ 879.4k | |
| Deputy GM & Executive Director | 6.9yrs | CN¥1.82m | 0.0076% HK$ 873.6k | |
| Executive Director | 1.7yrs | CN¥1.86m | no data | |
| Chief of Quality Division & Employee Representative Supervisor | 7.8yrs | no data | 0.0036% HK$ 419.0k | |
| Non-Executive Chairman | 10yrs | CN¥64.38m | 0.015% HK$ 1.7m | |
| Independent Non-Executive Director | 10yrs | CN¥100.00k | no data | |
| Supervisor | 7.9yrs | no data | 0.0076% HK$ 873.6k | |
| Chairman of the Board of Supervisors | 5.9yrs | no data | no data | |
| Independent Non Executive Director | 4.9yrs | CN¥100.00k | no data | |
| Independent Non-Executive Director | 4.7yrs | CN¥340.00k | 0.00045% HK$ 51.8k |
7.8yrs
Average Tenure
46yo
Average Age
Experienced Board: 1558's board of directors are considered experienced (7.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/14 03:53 |
| End of Day Share Price | 2025/05/14 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. is covered by 11 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ling Zhang | BNP Paribas Securities (Asia) |
| Ling Zhang | China Merchants Securities (HK) Co., Ltd |
| null null | CMB International Securities Limited |